drugset / Trial / NCT05289050

Analgesic Effect of Intraoperative Intravenous S-Ketamine During Total Knee Arthroplasty Surgery

NCT05289050

Phase 4 Unknown 144 enrolled Ling Dong
RandomizedParallel-groupSingle-blindOther

Summary

Severe acute pain after total knee arthroplasty surgery has multiple implications for hospitals and patients, monopolising resources and affecting the quality of life. S-ketamine inhibits N-methyl-d-aspartate (NMDA) receptor activation and attenuates central sensitization associated with hyperalgesia, opioid tolerance.Therefore, the primary aim of this trial was to investigate whether s-ketamine decreases pain and opioid consumption postoperatively in adult individuals undergoing total knee arthroplasty surgery.

Timeline

Start
2022-04-19
Primary completion
2024-09-01
Completion
2024-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 0.3 mg/kg Intravenous

Indications

No indication recorded.